http://orcid.org/0000-0002-2639-1180
References
- WebsterRGGovorkovaEAContinuing challenges in influenzaAnn. N. Y Acad. Sci.20141323 115 13910.1111/nyas.124624159436
- FlanneryBClippardJZimmermanRKEarly estimates of seasonal influenza vaccine effectiveness–United States, January 2015MMWR Morb. Mortal. Wkly. Rep.20156410154584793
- De ClercqELiGApproved antiviral drugs over the past 50 yearsClin. Microbiol. Rev.20162969574710.1128/CMR.00102-154978613
- GubarevaLVFallowsEMishinVPMonitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iARTEur. Surveill.2017221810.2807/1560-7917.ES.2017.22.18.30529
- HussainMGalvinHDHawTYNutsfordANHusainMDrug resistance in influenza A virus: the epidemiology and managementInfect. Drug Resist.20171012113410.2147/IDR.S1054735404498
- LudwigSPlanzOPleschkaSWolffTInfluenza-virus-induced signaling cascades: targets for antiviral therapy?Trends Mol. Med20039465210.1016/S1471-4914(02)00010-2
- KeenerABHost with the most: targeting host cells instead of pathogens to fight infectious diseaseNat. Med.20172352853110.1038/nm0517-528
- PlanzODevelopment of cellular signaling pathway inhibitors as new antivirals against influenzaAntivir. Res.20139845746810.1016/j.antiviral.2013.04.008
- LudwigSPlanzOInfluenza viruses and the NF-kappaB signaling pathway–towards a novel concept of antiviral therapyBiol. Chem.200838913071312
- LudwigSPleschkaSPlanzOWolffTRinging the alarm bells: signalling and apoptosis in influenza virus infected cellsCell Microbiol.2006837538610.1111/j.1462-5822.2005.00678.x
- WurzerWJEhrhardtCPleschkaSNF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagationJ. Biol. Chem.2004279309313093710.1074/jbc.M403258200
- NimmerjahnFDudziakDDirmeierUActive NF-kappaB signalling is a prerequisite for influenza virus infectionJ. Gen. Virol.2004852347235610.1099/vir.0.79958-0
- MazurIWurzerWJEhrhardtCAcetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activityCell Microbiol.200791683169410.1111/j.1462-5822.2007.00902.x
- HaasbachEReilingSJEhrhardtCThe NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virusAntivir. Res.20139933634410.1016/j.antiviral.2013.06.008
- EhrhardtCRuckleAHrinciusERThe NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistanceCell Microbiol.2013151198121110.1111/cmi.12108
- PintoRHeroldSCakarovaLInhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivoAntivir. Res.201192455610.1016/j.antiviral.2011.05.009
- KoppEGhoshSInhibition of NF-kappa B by sodium salicylate and aspirinScience199426595695910.1126/science.8052854
- GrilliMPizziMMemoMSpanoPNeuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activationScience19962741383138510.1126/science.274.5291.1383
- YinMJYamamotoYGaynorRBThe anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-betaNature1998396778010.1038/23948
- HuangRTDietschEAnti-influenza viral activity of aspirin in cell cultureN. Engl. J. Med.1988319797
- AmannRPeskarBAAnti-inflammatory effects of aspirin and sodium salicylateEur. J. Pharmacol.20024471910.1016/S0014-2999(02)01828-9
- HoakJCMechanisms of action: aspirinThromb. Res. Suppl.19834475110.1016/0049-3848(83)90357-2
- Le PhamDLeeJHParkHSAspirin-exacerbated respiratory disease: an updateCurr. Opin. Pulm. Med.201723899610.1097/MCP.0000000000000328
- KananiKGatoulisSCVoelkerMInfluence of differing analgesic formulations of aspirin on pharmacokinetic parametersPharmaceutics2015718819810.3390/pharmaceutics70301884588194
- DroebnerKHaasbachEDudekSEPharmacodynamics, pharmacokinetics, and antiviral activity of BAY 81-8781, a novel NF-kappaB inhibiting anti-influenza drugFront. Microbiol20178213010.3389/fmicb.2017.021305673638
- HaasbachEPauliEKSprangerRAntiviral activity of the proteasome inhibitor VL-01 against influenza A virusesAntivir. Res.20119130431310.1016/j.antiviral.2011.07.006
- MatrosovichMMatrosovichTGartenWKlenkHDNew low-viscosity overlay medium for viral plaque assaysVirol. J.200636310.1186/1743-422X-3-631564390
- HaasbachEMullerCEhrhardtCThe MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivoAntivir. Res201714217818410.1016/j.antiviral.2017.03.024
- HerrmannVLHartmayerCPlanzOGroettrupMCytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious diseaseJ. Control Release201521612113110.1016/j.jconrel.2015.08.019
- BaslerCFWangXMuhlbergerEThe Ebola virus VP35 protein functions as a type I IFN antagonistProc. Natl Acad. Sci. USA200097122891229410.1073/pnas.22039829717334
- KunzMGoebelerMBrockerEBGillitzerRIL-8 mRNA expression in primary malignant melanoma mRNA in situ hybridization: sensitivity, specificity, and evaluation of dataJ. Pathol.200019241341510.1002/1096-9896(200011)192:3<413::AID-PATH738>3.0.CO;2-1
- LudwigSInfluenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathwayJ. Biol. Chem.2001276109901099810.1074/jbc.M009902200
- KoebrichRRudolfGStahlhofenWA mathematical model of mass deposition in manAnn. Occup. Hyg.1994381523
- HillesheimANordhoffCBoergelingYLudwigSWixlerVbeta-catenin promotes the type I IFN synthesis and the IFN-dependent signaling response but is suppressed by influenza A virus-induced RIG-I/NF-kappaB signalingCell Commun. Signal20141210.1186/1478-811X-12-294021428
- LudwigSWangXEhrhardtCThe influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factorsJ. Virol.200276111661117110.1128/JVI.76.21.11166-11171.2002136597
- NackenWAnhlanDHrinciusERActivation of c-jun N-terminal kinase upon influenza A virus (IAV) infection is independent of pathogen-related receptors but dependent on amino acid sequence variations of IAV NS1J. Virol.2014888843885210.1128/JVI.00424-144136289
- MorrisTStablesMHobbsAEffects of low-dose aspirin on acute inflammatory responses in humansJ. Immunol.20091832089209610.4049/jimmunol.0900477
- TonerPMcAuleyDFShyamsundarMAspirin as a potential treatment in sepsis or acute respiratory distress syndromeCrit. Care20151910.1186/s13054-015-1091-64619098
- MitznerDDudekSEStudtruckerNPhosphorylation of the influenza A virus protein PB1-F2 by PKC is crucial for apoptosis promoting functions in monocytesCell Microbiol.2009111502151610.1111/j.1462-5822.2009.01343.x
- MuhlbauerDDzieciolowskiJHardtMInfluenza virus-induced caspase-dependent enlargement of nuclear pores promotes nuclear export of viral ribonucleoprotein complexesJ. Virol.2015896009602110.1128/JVI.03531-144442457